{
    "nct_id": "NCT05106192",
    "official_title": "Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.",
    "inclusion_criteria": "1. > 18 years of age\n2. Diagnosed with primary cutaneous lymphoma defined by either:\n\n   * A board-certified dermatologist, OR\n   * Dermatology Nurse Practitioner, OR\n   * Skin punch biopsy\n3. The presence of plaque-type primary cutaneous lymphoma lesions with at least two plaques that are at least two cm² in areas of the trunk, buttocks, or extremities that are either:\n\n   * Symmetrically located on contralateral body site OR\n   * Within the same body site but separated by ≥ 1 cm\n   * Both plaques must be similar in size as much as possible\n4. Able to give informed consent under IRB approval procedures\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Known allergy or hypersensitivity to triamcinolone acetonide\n2. Known allergy to topical bexarotene or topical nitrogen mustard\n3. Pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4 weeks after the study.\n4. Inability to provide informed consent\n5. Diagnosis of erythrodermic mycosis fungoides or Sezary syndrome\n6. Use of topical corticosteroids to target lesions within 1 week prior to baseline visit\n7. Use of radiation therapy to target lesions within 1 week prior to baseline visit",
    "miscellaneous_criteria": ""
}